<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0370712</journal-id>
<journal-id journal-id-type="pubmed-jr-id">3660</journal-id>
<journal-id journal-id-type="nlm-ta">Exp Neurol</journal-id>
<journal-id journal-id-type="iso-abbrev">Exp. Neurol.</journal-id>
<journal-title-group>
<journal-title>Experimental neurology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0014-4886</issn>
<issn pub-type="epub">1090-2430</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28392281</article-id>
<article-id pub-id-type="pmc">5630478</article-id>
<article-id pub-id-type="doi">10.1016/j.expneurol.2017.04.001</article-id>
<article-id pub-id-type="manuscript">NIHMS867110</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Human Stem Cell Modeling in Neurofibromatosis type 1 (NF1)</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wegscheid</surname>
<given-names>Michelle L.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Anastasaki</surname>
<given-names>Corina</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gutmann</surname>
<given-names>David H.</given-names>
</name>
</contrib>
<aff id="A1">Department of Neurology, Washington University School of Medicine, St. Louis MO 63110</aff>
</contrib-group>
<author-notes>
<corresp id="FN1">Address correspondence to: David H. Gutmann, MD, PhD, Department of Neurology, Washington University School of Medicine, Box 8111, 660 South Euclid Avenue, St. Louis, MO 63110. 314-362-7379 (phone); 314-362-2388 (fax); <email>gutmannd@wustl.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>11</day>
<month>4</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>06</day>
<month>4</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>1</month>
<year>2019</year>
</pub-date>
<volume>299</volume>
<issue>Pt B</issue>
<fpage>270</fpage>
<lpage>280</lpage>
<!--elocation-id from pubmed: 10.1016/j.expneurol.2017.04.001-->
<abstract>
<p id="P2">The future of precision medicine is heavily reliant on the use of human tissues to identify the key determinants that account for differences between individuals with the same disorder. This need is exemplified by the neurofibromatosis type 1 (NF1) neurogenetic condition. As such, individuals with NF1 are born with a germline mutation in the <italic>NF1</italic> gene, but may develop numerous distinct neurological problems, ranging from autism and attention deficit to brain and peripheral nerve sheath tumors. Coupled with accurate preclinical mouse models, the availability of NF1 patient-derived induced pluripotent stem cells (iPSCs) provides new opportunities to define the critical factors that underlie NF1-associated nervous system disease pathogenesis and progression. In this review, we discuss the generation and potential applications of iPSC technology to the study of NF1.</p>
</abstract>
<kwd-group>
<kwd>NF1</kwd>
<kwd>neurodevelopment</kwd>
<kwd>neurofibroma</kwd>
<kwd>iPSC</kwd>
<kwd>stem cell</kwd>
<kwd>optic pathway glioma</kwd>
<kwd>retinal ganglion cell</kwd>
<kwd>microglia</kwd>
<kwd>tumor</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>